USPTO v. Gilead Sciences: Federal Circuit PrEP Patent Appeal Voluntarily Dismissed
The U.S. Patent and Trademark Office and Gilead Sciences jointly dismissed a Federal Circuit appeal involving four government-held patents covering HIV pre-exposure prophylaxis regimens — including Truvada and Descovy for PrEP. The proceeding closed in 189 days with each side bearing its own costs, leaving the merits of the underlying PrEP patent dispute unresolved at the appellate level.
U.S. Government and Gilead Jointly End Federal Circuit PrEP Patent Appeal
Case No. 24-2069 was filed at the Court of Appeals for the Federal Circuit on July 12, 2024, with the United States Patent and Trademark Office as plaintiff-appellant and Gilead Sciences, Inc. as defendant-appellee. The dispute centred on four U.S. patents — US9044509B2, US9937191B2, US9579333B2, and US10335423B2 — which the U.S. government asserts cover CDC-invented pre-exposure prophylaxis (PrEP) regimens, including the FTC/TDF combination commercialised as Truvada for PrEP and the FTC/TAF combination in Descovy for PrEP.
The appeal was terminated on January 17, 2025, by agreed order under Federal Rule of Appellate Procedure 42(b), which governs voluntary dismissal at the appellate level. The court’s order records that ‘the parties having so agreed,’ the proceeding is dismissed, with each side bearing its own costs. Critically, no merits ruling was issued: the Federal Circuit made no finding on patent validity, infringement, or the scope of the government’s PrEP patent rights. The cost-neutral outcome suggests neither party extracted a concession that would typically accompany a one-sided dismissal.
The 189-day duration — well below the Federal Circuit’s typical timeline for substantive patent appeals — is consistent with the parties reaching an out-of-court resolution or strategic agreement to withdraw before briefing was complete. The public record does not disclose any underlying settlement terms, licensing arrangement, or consent agreement that may have prompted the mutual dismissal. What remains unknown is whether the underlying district court proceedings remain live, whether any licensing terms were negotiated, and what the government’s long-term enforcement posture will be with respect to Gilead’s PrEP product lines.
Filing to Voluntary dismissal in 189 days
189 days — faster than the Federal Circuit median for patent appeals (~18 months), consistent with agreed dismissal
Voluntarily dismissed: what the agreed appellate exit means for both parties
Fed. R. App. P. 42(b): voluntary dismissal at appellate level
Rule 42(b) allows parties to dismiss a Federal Circuit appeal by stipulation at any time. Unlike a merits ruling, a 42(b) dismissal does not adjudicate patent validity or infringement — it simply terminates the appellate proceeding. The underlying district court judgment, if any, is left undisturbed unless the dismissal is part of a broader settlement that resolves all proceedings. No precedential value is created.
No merits adjudicationWith or without prejudice? The public record is silent
The order records voluntary dismissal under Rule 42(b) but does not specify whether the dismissal is with or without prejudice to refiling or re-litigation. Fed. R. App. P. 42(b) dismissals are generally treated as final as to the appeal itself, but do not necessarily bar fresh proceedings in the district court. Without a publicly disclosed settlement agreement or consent decree, it is not possible to determine whether the government retains the right to pursue these PrEP patent claims again.
Prejudice terms undisclosedUSPTO’s PrEP patent enforcement leaves appellate question open
By agreeing to dismiss, the USPTO and the U.S. government neither won nor lost on appeal. The four CDC-developed PrEP patents remain on the register with no Federal Circuit ruling on their validity or Gilead’s alleged infringement. The government’s decision to jointly dismiss — rather than press the appeal — may suggest a strategic recalibration, but the absence of a public settlement means enforcement risk to Gilead cannot be formally ruled out.
No validity ruling issuedGilead avoids adverse appellate ruling but uncertainty persists
For Gilead, a voluntary dismissal without a merits ruling is a neutral-to-positive short-term outcome: no Federal Circuit finding of infringement of the government’s PrEP patents. However, the absence of a definitive ruling means Gilead cannot rely on this dismissal as a precedential shield against future government enforcement. Commercial exposure over Truvada and Descovy for PrEP may persist depending on any undisclosed licensing or settlement terms.
Exposure not formally extinguishedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | United States and Trademark Office | Individual | U.S. federal agency — holder of US9044509B2 and three further PrEP method patentsSearch in Eureka ↗ |
| Defendant | Gilead Sciences, Inc. | Company | Global biopharmaceutical company; manufacturer of Truvada and Descovy for PrEP HIV prevention tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Carrie Rosato Trial | Attorney | Counsel for United States and Trademark OfficeSearch in Eureka ↗ |
| Plaintiff counsel | Jhaniel James | Attorney | Counsel for United States and Trademark OfficeSearch in Eureka ↗ |
| Plaintiff counsel | Philip Charles Sternhell | Attorney | Counsel for United States and Trademark OfficeSearch in Eureka ↗ |
| Plaintiff counsel | Scott David Bolden Director | Attorney | Counsel for United States and Trademark OfficeSearch in Eureka ↗ |
| Plaintiff counsel | Walter W. Brown Senior Litigation Counsel | Attorney | Counsel for United States and Trademark OfficeSearch in Eureka ↗ |
| Defendant counsel | David B. Bassett | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Mark Christopher Fleming | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Ronald Machen Jr. | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Timothy A. Cook | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Vinita Ferrera | Attorney | Counsel for Gilead Sciences, Inc.Search in Eureka ↗ |
| Defendant law firm | Wilmer Cutler Pickering Hale & Dorr LLP | Law Firm | Representing Gilead Sciences, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The order’s phrasing — ‘the parties having so agreed’ — confirms this is a consensual exit under Fed. R. App. P. 42(b), not a unilateral withdrawal or sua sponte dismissal. The Federal Circuit issued no opinion on patent validity, claim construction, or infringement of the four CDC PrEP patents. The cost-neutral directive (‘each side shall bear their own costs’) is consistent with a negotiated resolution but provides no signal as to which party held the stronger appellate position. The underlying merits remain legally undecided.
US9044509B2 and three co-patents — CDC-developed HIV PrEP dosing regimens
The four asserted patents — US9044509B2, US9937191B2, US9579333B2, and US10335423B2 — are assigned to the U.S. Department of Health and Human Services and cover CDC-developed methods of using antiretroviral combinations for HIV pre-exposure prophylaxis (PrEP). The patents claim specific regimens involving emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) and emtricitabine/tenofovir alafenamide (FTC/TAF), the active combinations in Truvada and Descovy for PrEP respectively. Application dates span multiple years, reflecting iterative prosecution across the PrEP dosing and administration landscape.
These patents sit at the intersection of public health policy and commercial pharmaceutical IP. Gilead’s Truvada and Descovy for PrEP are market-leading HIV prevention products generating billions in annual revenues. If the government’s method claims are valid and infringed, they would constitute a direct royalty obligation — or licensing leverage — over Gilead’s core PrEP franchise. For generic manufacturers entering the PrEP market, and for any company developing next-generation antiretroviral prophylaxis, understanding the claim scope of these four patents is strategically essential.
Should you run an FTO against US9044509B2 and the CDC’s PrEP patent portfolio?
Any company developing, manufacturing, or commercialising HIV PrEP products — including FTC/TDF or FTC/TAF formulations, new nucleotide-based prophylaxis regimens, or long-acting PrEP alternatives — should assess freedom-to-operate against these four CDC patents. The voluntary dismissal of the Federal Circuit appeal does not invalidate or limit the claims; the patents remain enforceable. Generic entrants, combination ART developers, and public health procurement entities face the most direct exposure.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map the independent and dependent claims of US9044509B2, US9937191B2, US9579333B2, and US10335423B2 against your product pipeline, identify prior art relevant to validity, and flag prosecution history estoppel issues — all in a fraction of the time of manual claim charting. With government enforcement posture uncertain, proactive FTO analysis is the prudent first step.
Run a freedom-to-operate analysis on US9044509B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit PrEP and antiretroviral patent appeals
Browse Federal Circuit and district court cases involving government-held biomedical patents, HIV antiretroviral IP, and CDC or NIH enforcement actions in the PrEP space.
What this case signals for the HIV prevention and biopharmaceutical IP landscape
A mutual Federal Circuit exit over CDC-held PrEP patents raises pointed questions about government patent enforcement strategy and Gilead’s long-term licensing exposure.
Government-held biomedical patents are an active enforcement vector
The CDC’s assertion of PrEP method patents against one of the world’s largest HIV treatment companies confirms that U.S. federal agencies will litigate — and appeal — against commercial holders of competing products. Any company operating in the antiretroviral or PrEP space should map its exposure to government-owned patents, not just private sector IP.
A cost-neutral exit does not mean the dispute is resolved
The ‘each side bears own costs’ formula and the absence of disclosed settlement terms means the underlying PrEP patent rights remain contested. Companies monitoring Gilead’s FTC/TDF and FTC/TAF product lines should treat this dismissal as a pause, not a resolution. Continued FTO monitoring of US9044509B2 and its co-pending patents is warranted.
Office v Gilead — key questions answered
The Federal Circuit issued no merits ruling. The parties jointly dismissed the appeal under Fed. R. App. P. 42(b) on January 17, 2025. Each side bore its own costs. No determination was made on the validity or infringement of the four CDC PrEP patents at issue.
Four patents were involved: US9044509B2, US9937191B2, US9579333B2, and US10335423B2. These are CDC-developed patents covering HIV pre-exposure prophylaxis regimens using FTC/TDF (the Truvada for PrEP combination) and FTC/TAF (the Descovy for PrEP combination).
A Rule 42(b) dismissal terminates the appellate proceeding by agreement but does not adjudicate validity, infringement, or claim scope. The four CDC PrEP patents remain in force. The order does not publicly disclose whether any licensing agreement, consent decree, or settlement was reached alongside the dismissal.
Not definitively. No infringement finding was made, so Gilead cannot be held liable on this appeal. However, because no invalidity ruling was issued either, the government retains the right to pursue these patents in other proceedings — depending on any confidential settlement terms not reflected in the public record.
The USPTO was represented by attorneys including Philip Charles Sternhell, Walter W. Brown (Senior Litigation Counsel), and Scott David Bolden (Director). Gilead Sciences was represented by Wilmer Cutler Pickering Hale & Dorr LLP, with counsel including David B. Bassett, Mark Christopher Fleming, Ronald Machen Jr., Timothy A. Cook, and Vinita Ferrera.
PatSnap Eureka searches patents and litigation data to answer instantly.